| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics | Frank Vinluan | 04/08/20 | Boston |
| Creating Consistent Value in Biotech Without Diluting Stakeholders | Alexis Peyroles | 04/07/20 | National |
| GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months | Frank Vinluan | 04/06/20 | San Francisco |
| Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic | Sarah de Crescenzo | 04/03/20 | Boston |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus | Dan Stanton | 03/31/20 | Europe |
| Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance | Frank Vinluan | 03/27/20 | Europe |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes | Frank Vinluan | 03/23/20 | Europe |
| Qiagen Juices RNA Extraction Kit Capacity to Feed Coronavirus Test Needs | Sarah de Crescenzo | 03/17/20 | National |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund | Dan Stanton | 03/11/20 | Europe |
| Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod | Frank Vinluan | 03/09/20 | Europe |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Sanofi Wins FDA Nod for Combo Therapy in Multiple Myeloma | Sarah de Crescenzo | 03/03/20 | National |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK | Frank Vinluan | 02/27/20 | New York |
| Bicycle Therapeutics Lands $30M From Genentech in New Cancer R&D Pact | Frank Vinluan | 02/25/20 | Boston |
| Esperion’s FDA-Approved Cholesterol Drug Priced Even Lower Than Expected | Frank Vinluan | 02/24/20 | Detroit Ann Arbor |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff | Frank Vinluan | 02/05/20 | New York |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report | Gareth Macdonald | 01/28/20 | National |
| Quench Bio Springs From Atlas With $50M for a New Take on Inflammation | Frank Vinluan | 01/27/20 | Boston |
